A question of ethics: selling autologous stem cell therapies flaunts professional standards

Stem Cell Res. 2014 Nov;13(3 Pt B):647-53. doi: 10.1016/j.scr.2014.04.014. Epub 2014 Apr 29.


The idea that the body's own stem cells could act as a repair kit for many conditions, including cardiac repair, underpins regenerative medicine. While progress is being made, with hundreds of clinical trials underway to evaluate possible autologous cell-based therapies, some patients and physicians are not prepared to wait and are pursuing treatments without evidence that the proposed treatments are effective, or even safe. This article explores the inherent tension between patients, practitioners and the need to regulate the development and commercialization of new cellular therapies--even when the cells come from the patient.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell- and Tissue-Based Therapy / economics
  • Cell- and Tissue-Based Therapy / ethics*
  • Cell- and Tissue-Based Therapy / psychology
  • Humans
  • Patients / psychology
  • Physicians / ethics
  • Physicians / psychology
  • Regenerative Medicine / economics
  • Regenerative Medicine / ethics
  • Stem Cell Transplantation / economics
  • Stem Cell Transplantation / ethics*
  • Stem Cell Transplantation / psychology
  • Transplantation, Autologous / economics
  • Transplantation, Autologous / ethics
  • Transplantation, Autologous / psychology